Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain–Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain–Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma

Published:2020-03-31 Issue:1 Volume:72 Page:155-168
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Leung Carmen Oi Ning¹,Tong Man²,Chung Katherine Po Sin¹,Zhou Lena²,Che Noélia²,Tang Kwan Ho³,Ding Jin⁴,Lau Eunice Yuen Ting⁵,Ng Irene Oi Lin⁶⁷^ORCID,Ma Stephanie²⁷^ORCID,Lee Terence Kin Wah¹⁸^ORCID

Affiliation:

1. Department of Applied Biology and Chemical Technology The Hong Kong Polytechnic University Hong Kong

2. School of Biomedical Sciences Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong

3. Laura and Isaac Perlmutter Cancer Center New York University School of Medicine NYU Langone Health New York NY

4. The International Cooperation Laboratory on Signal Transduction Eastern Hepatobiliary Surgery Hospital Shanghai China

5. Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong

6. Department of Pathology The University of Hong Kong Hong Kong

7. State Key Laboratory for Liver Research The University of Hong Kong Hong Kong

8. State Key Laboratory of Chemical Biology and Drug Discovery The Hong Kong Polytechnic University Hong Kong

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30989

Reference33 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

3. Sorafenib in Advanced Hepatocellular Carcinoma

4. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

5. The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The combination of SHP099 inhibits the malignant biological behavior of L-OHP/5-FU-resistant colorectal cancer cells by regulating energy metabolism reprogramming;Biochemical and Biophysical Research Communications;2024-10

2. Sorafenib-mediated cleavage of p62 initiates cellular senescence as a mechanism to evade its anti-hepatocellular carcinoma efficacy;Oncogene;2024-09-04

3. CuET overcomes regorafenib resistance by inhibiting epithelial-mesenchymal transition through suppression of the ERK pathway in hepatocellular carcinoma;Translational Oncology;2024-09

4. Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules;European Journal of Medicinal Chemistry;2024-09

5. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24